Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

BetterLife Pharma Inc C.BETR

Alternate Symbol(s):  BETRF

Healthcare
BetterLife Pharma Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing two compounds, BETR-001 and BETR-002, to treat neuro-psychiatric and neurological disorders. BETR-001 is a non-hallucinogenic Lysergic Acid Diethylamide (LSD) derivative. BETR-001 mimics the projected therapeutic properties of LSD without causing its undesirable side effects such as hallucinations and cardiac toxicity. BETR-001 is a therapy to treat debilitating psychiatric disorders with high unmet need, such as major depressive disorder and anxiety disorders; as well as neurological disorders such as neuropathic pain. BETR-002 is a formulation of a derivative of dihydrohonokiol, a known anti-anxiety compound for treatment of benzodiazepine dependency, anxiety and spasticity. The Company also owns a drug candidate for the treatment of viral infections such as COVID-19. The Company’s subsidiaries include MedMelior Inc., BetterLife Pharma US Inc. and Blife Therapeutics Inc.


CSE:BETR - Post by User

BetterLife Pharma Inc
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(3)
•••
Post by mattusvion Jul 16, 2021 8:20am
340 Views
Post# 33558244

Great News for BETR. stocktwits: 87 watchers !

Great News for BETR. stocktwits: 87 watchers !

$BETRF is pleased to announce early positive in vitro results of its COVID-19 anti-viral, recombinant human interferon alpha-2b, from the Dr. Stephen Barr Laboratory and state-of-the-art ImPaKT Facility at Western University (“UWO”).


https://www.newsquantified.com/betrf/stock-report/betterlife-pharma-inc-early-results-preclinical-study-showing-08mueb#app0

There are only 87 "watchers" of BETRF on Stocktwits!

Go over to stocktwits and click "watch"... let's get some interest going in this company!
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities